Impaired Humoral Response to Second Dose of BNT162b2 Messenger RNA COVID-19 Vaccine in Kidney Transplant Recipients in Japan: Prospective Observational Study
American Journal of Transplantation
; 22(Supplement 3):771, 2022.
Article
in English
| EMBASE | ID: covidwho-2063506
ABSTRACT
Purpose:
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on solid organ transplant (SOT) recipients, with mortality rate up to 22%. The effect of SARS-CoV-2 vaccination are known to have poor responses even after 2nddose in SOT in Europe and the United States. We investigated immune response by detecting SARS-CoV-2 antibody (Ab) post two-doses of messenger RNA (mRNA)-based SARS-CoV-2 vaccinesin Japanese renal transplant recipients as prospective observational study. Method(s) 352 recipients who have no history of COVID-19, were confirmed no SARS-CoV-2 antibody before vaccination and received 2nd dose of BNT162b2 mRNA vaccine are enrolled in this study.Antibody detection test was performed by using the Roche Elecsys Anti-SARS-CoV-2 immunoassay after more than 4weeks following 2nddose of it. Negative for N-Ab (0.4U/ml>) and positive for S-Ab (0.8U/ml<) considered to be positive for SARS-CoV-2 Ab.As a healthy control, SARS-CoV-2 Ab was determined in 990 healthy volunteers (HV) as well as 98 kidney donors as control for chronic kidney disease (Donor). Result(s) The rate of positive for S-Ab was 56.2% in recipients while that was 100% in HV and Donor. Titer of S-Ab (U/ml) was 77 in recipients although that was 2400 in HV and 1100 in Donor, respectively, which indicating significantly lower in recipients. (Fig. 1) Interestingly, positive rate for s-Ab by detecting time following 2ndvaccination in recipients was 44% in 4-6 weeks, 54% in 6-8 weeks, 67% in 8-10 weeks, 72% in 10-12 weeks, 80% in 12-weeks, which suggesting that recipients have delayed response to 2ndvaccination while that was 100% in any time point in HV and Donor. (Fig.2) Moreover, to elucidate difference between responder (n=198) and non-responder (n=154) in recipients, we compared clinical background that influencedoutcome. In non-responder, there were significant difference in older age at vaccination, less lymphocyte, previousdoses of rituximab, concomitant use of mycophenolate mofetil and oral administration of more than three immunosuppressants. (Table.1) Conclusion(s) Kidney recipients have delayed response with lower titer of SARSCoV- 2 antibodyfollowing second dose of mRNA-based COVID-19 Vaccine.
aged; antibody detection; chronic kidney failure; conference abstract; controlled study; coronavirus disease 2019; drug therapy; female; human; human cell; humoral immunity; immune response; immunoassay; Japan; kidney donor; kidney graft; lymphocyte; major clinical study; male; nonhuman; observational study; oral drug administration; positivity rate; prospective study; Severe acute respiratory syndrome coronavirus 2; surgery; vaccination; immunosuppressive agent; messenger RNA; mycophenolate mofetil; rituximab; RNA vaccine; SARS-CoV-2 antibody; tozinameran
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
American Journal of Transplantation
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS